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Abstract
Background: Mitochondrial outer membrane permeabilization (MOMP) is one of the
most important points in the majority of apoptotic signaling cascades and it is
controlled by a network of interactions between the members of the Bcl-2 family.
Methods: To understand the role of individual members of this family within the
MOMP regulation, we have constructed a Boolean network-based model of
interactions between the Bcl-2 proteins.
Results: Computational simulations have revealed the existence of trapping states
which, independently from the incoming stimuli, block the occurrence of MOMP. Our
results emphasize the role of the antiapoptotic protein Mcl-1 in the majority of these
configurations. We demonstrate here the importance of the Bid and Bim for activation
of effectors Bax and Bak, and the irreversibility of this activation. The model further
points to the antiapoptotic protein Bcl-w as a key factor preventing Bax activation.
Conclusions: In spite of relative simplicity, the Boolean network-based model
provides useful insight into main functioning logic of the Bcl-2 switch, consistent with
experimental findings.
Keywords: Boolean network, Bcl-2 family, Apoptosis, Mitochondrial outer membrane
permeabilisation
Introduction
Apoptosis is a process of programmed cellular death, distinct from necrosis [1,2],
which can be well distinguished by its morphology [3]. It is an important homeostatic
mechanism, and its defects may cause a variety of serious diseases, including neu-
rodegenerative disorders [4], autoimmune diseases [5], or even cancer [6-8]. Signals
leading to an apoptosis initiation can originate from an extracellular environment or
from a cell’s internal space [8,9]. Apoptotic signals further proceed through an apop-
totic signaling and regulatory network, that contains several control points [8,9]. One,
highly important of such points is formed by a family of Bcl-2 (B-cell lymphoma 2)
proteins [10,11]. An interplay between the Bcl-2 family’s members controls one of the
most crucial apoptotic events - the mitochondrial outer membrane permeabilization
(MOMP) [12,13].
MOMP allows the release of apoptotic key players - Smac/DIABLO and a cytochrome
c, from the mitochondrial, intermembrane space to the cytosol [12,13]. In the pres-
ence of ATP, released cytochrome c binds to a cytosolic protein Apaf-1, causing Apaf-1
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oligomerization and the recruitment of an inactive pro-caspase-9, leading to the for-
mation of a multi-protein complex known as an apoptosome [14-16]. Within the apop-
tosome, pro-caspase-9 subsequently undergoes processing and activation [14-16]. The
active caspase-9 proteolytically activates caspase-3 [17]. Smac/DIABLO, once released to
the cytosol, inhibits XIAP (X-linked inhibitor of apoptosis) - themost prominent suppres-
sor of caspases -3 and -9 [18]. Caspase-3 and other effector caspases (caspases -6 and -7)
are the primary executioners of apoptosis [8,19]. Activation of these makes the point of
no-return, after which the irreversible phase of apoptosis is executed [20]. Although other,
mitochondria-independent apoptotic signaling pathways also exist [21], the mitochon-
drial (also known as intrinsic) pathway is the major one [22].
The MOMP is carried in “all or nothing” manner, where no intermediate MOMP states
are possible. A control mechanism of such an event can be modeled by, in terms of
complex systems science, a bistable switch.
This interesting property has made the Bcl-2 family an attractive subject of mathemati-
cal modeling and computer simulations. There are several works regarding modeling and
a simulation of the Bcl-2 family and the control ofMOMP, revealing and examining a vari-
ety of non-linear system behaviors such as robustness, stimulus-response ultrasensitivity
[23] and bistability [24-26]. Besides these, the Bcl-2 family was involved in several other,
more general models of apoptosis signaling [27-29].
All the above-mentioned models are continuous, dynamically simulating the chemical
reaction kinetics of the studied system. These models reduce their complexity through
aggregating proteins with similar function into functional groups. The most prominent
group member is taken as the representative of the given group. Although the above-
mentioned models of Bcl-2 regulatory network are of various levels of detail, they all
adopt such simplification. This is done usually by grouping the Bcl-2 family’s mem-
bers into three or four groups according to their structural and functional classification.
Such division provides reasonable trade-offs between the model’s simplicity and plau-
sibility. However, when grouped together, certain important functional specifics are
ignored.
The critical factor which limits the development of more detailed, quantitative models
of the Bcl-2 family is the availability of quantitative data, that is still a systems biol-
ogy bottleneck [30]. However, the works of Chen et al [31] and Dai et al [32] provided
affinity measurements of most Bcl-2 protein–protein bindings – major type of Bcl-2
intra-familiar interactions. Furthermore, Dussmann and colleagues [33] measured single-
cell dynamics of MOMP commitment and supported his measurements by Bcl-2 family
model similar to those mentioned above. Recently, Lindner et al [34] translated the
western-blot quantifications of several Bcl-2 proteins and clinical findings into currently
the most detailed model of great predictive power.
Despite the ever growing amount of experimental data, there remain quantitative
parameters that need to be supplemented by relevant experimental in vivomeasurements.
The absence of these parameters provides an opportunity for less demanding qualitative
description using the discrete state models. In this work we propose such model of the
Bcl-2 family mediated regulation of MOMP based on Boolean network modeling. The
Boolean network (BN) approach is one of the best suited approaches to the qualitative
modeling of complex biological systems [30,35]. BN, first introduced in the late 1960s
[36], was originally used to model gene regulatory networks and signaling pathways [37].
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Although, BN does not model continuous time dynamics of the studied system, it may
reveal properties of state transition dynamics [37]. For the first time BN model involving
members of the Bcl-2 family appeared in work of Calzolari et al [38]. Mai and Liu [35] and
fewmonths later Schlatter et al [30], published themost recent BN-basedmodels of apop-
tosis, both containing simplified mechanism of Bcl-2 family MOMP control. However, as
far as we know, no comprehensive modeling work involving the whole Bcl-2 family has
been published yet.
Modeling and simulations
Model and its biological relevance
Bcl-2 family’s members are functionally classified as either antiapoptotic, or proapop-
totic. Structurally, Bcl-2 proteins can be categorized according to the number of Bcl-2
homology domains (BH) in their α-helical regions [8,39]. Antiapoptotic members (Mcl-
1, A1, Bcl-xL, Bcl-2, Bcl-w and Bcl-B) are characterized by the presence of four BH
domains (BH1-4) [40,41]. Their role is to prevent MOMP by inhibition of proapoptotic
family members [40,41]. Proapoptotic members can be divided to BH3-only proteins
and multidomain proteins - effectors [8]. BH3-only proteins can be further subdivided
based upon their role in apoptotic signaling. BH3-only subgroup members, termed sen-
sitizers (Noxa, Bad, Puma, Hrk, Bmf and Bik), can only bind to antiapoptotic Bcl-2
proteins, forming inactive dimers [39]. Members of another BH3 subgroup, termed acti-
vators (Bim and Bid), can act in the same way [39], but in addition, activators can
directly activate effectors [40,42]. Effectors, once activated, undergo oligomerization and
form pores in mitochondrial outer membrane (MOM), leading eventually to MOMP.
[13,43]. Therefore, effectors are the primary target of inhibition by their antiapoptotic
relatives [42].
Altogether, interactions between Bcl-2 family members can be classified into only
three types: i) Binding and mutual inhibition between antiapoptotic and BH3-only pro-
teins. ii) Binding and mutual inhibition between antiapoptotic proteins and effectors. iii)
Activation of effectors by BH3-only proteins. However, the situation ceases be so sim-
ple when we focus on the interaction between individual molecules. E.g., the BH3-only
sensitizer Noxa can bind to and inhibit only two antiapoptotic proteins (see Table 1)
[8,31,39], but the other BH3-only sensitizer, Puma is able to inhibit five of six major
antiapoptotic proteins [8,31,39]. On the other hand, while it seems that the antiapop-
totic protein Bcl-B is not bound or inhibited by any of the BH3-only proteins [44],
the other antiapoptotic protein Bcl-xL is bound by seven of them [8,31]. There is also
a strong asymmetry in the level of inhibition of effectors by antiapoptotic proteins.
While Bak is inhibited only by three antiapoptotic proteins, Bax is inhibited by all six of
them [8,39].
The knowledge about interactions between Bcl-2 family members was encoded in the
Boolean network-based model we present here. The model contains 14 nodes, represent-
ing the Bcl-2 family’s members. Each member of the Bcl-2 family is represented by one of
the nodes. The only exception was Bad & Bmf and Hrk & Bik pairs, coupled together due
to their identical intra-familiar interaction profiles (see Table 1).
The whole model contains 34 connections between nodes, each representing one
molecular interaction.
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Table 1 Binding and inhibition between individual members of the Bcl-2 family




Mcl-1 Myeloid cell leukemia sequence-1 Noxa, Bim, Puma, Bax, Bak [8,31]
Bcl-2 B-cell lymphoma 2 Bad, Bim, Puma, Bmf, Bax [8,31]
A1 Bcl-2 related protein Noxa, Bim, Puma, tBid, Hrk, Bik, Bax, Bak [8,31]
Bcl-xL Bcl-2-like Bad, Bim, Puma, tBid, Hrk, Bmf, Bik, Bak, Bax [8,31]
Bcl-w Bcl-2-like-2 Bad, Bim, Puma, tBid, Hrk, Bmf, Bik, Bax [8,31]
Bcl-B Bcl-2-like-10 Bax [44]
BH3-only
Members:
Noxa Phorbol-12-myristate-13-acetate-induced Mcl-1, A1 [8,31,39]
protein 1
Bad Bcl-2 antagonist of cell death Bcl-xL, Bcl-w, Bcl-2 [8,31,39]
Bim Bcl-2like-11 Bcl-xL, Bcl-w, Bcl-2, Mcl-1, A1 [8,31,39]
Puma Bcl-2-binding component-3 Bcl-xL, Bcl-w, Bcl-2, Mcl-1, A1 [8,31,39]
tBid truncated BH3-interacting Bcl-xL, Bcl-w, A1 [31,39]
domain death agonist
Hrk Harakiri Bcl-xL, Bcl-w, A1 [31]
Bmf Bcl-2-modifying factor Bcl-xL, Bcl-w, Bcl-2 [31,39]
Bik Bcl-2-interacting killer Bcl-xL, Bcl-w, A1 [31]
Effectors:
Bak Bcl-2-antagonist/killer-1 Bcl-xL, Mcl-1, A1 [8,39]
Bax Bcl-2-associated X protein Bcl-xL, Bcl-w, Bcl-2, Bcl-B, Mcl-1, A1 [8,39]
Transition rules
Each of the nodes can be either active or inactive. Each of the nodes is affected by received
inputs from one or several other upstream nodes. The state of the node i in the next time
step si(t + 1) is defined by the following transition rule:
si(t + 1) =
⎧⎪⎨
⎪⎩
1, i > 0,
si(t), i = 0,
0, i < 0,
(1)




Here, rij specifies the relation of the j-th node to i-th node, and it may have three pos-
sible values: rij = 1 if j-th node activates i-th node, rij = −1 if j-th node inhibits i-th
node and rij = 0, if nodes j and i are not connected (the relationships between nodes are
depicted in the Figure 1). The value of ei defines the expression of the protein represented
by the i-th node (see following section).
Since Bcl-2 family members inhibit each other bymutual binding and formation of inac-
tive dimers, our model treats the inhibitory relationships between two nodes as bipartite
(if rij = −1, then rji = −1).
During the simulation, the states of all nodes are step-wise simultaneously reevaluated
according to the transition rule described by the eq. (1), until the simulation is terminated.





















































Figure 1 Relationships between the nodes of the model. The red squares represent the negative
relationships of the inputs toward the related nodes. Negative relationship corresponds to mutual binding
and inhibition between two members of the Bcl-2 family (see Table 1). The blue squares represent the
positive relationships of the inputs toward the related nodes. Positive relation corresponds to activation of
the effectors Bax/Bak by certain BH3-only proteins - activators (tBid, Bim) [40,41].
Influence of the external conditions
The transition function of the i-th node is dependent on the value of ei. The value of
binary vector E (E = {e1, e2, . . . e16}) represents here, what we termed the “expression” of
the Bcl-2 family proteins. The value ei = 1, corresponds to the cellular conditions allow-
ing the synthesis and, if required, the post-translational/post-transcriptional activation
(e. g. activation of Bid requires proteolytic cleavage by Caspase-8 [45]) of the i-th protein.
Alternatively, the value ei = 0, corresponds to the conditions preventing the synthesis
and/or post-translations activation of the i-th protein.
Since the model contains 14 nodes, the vector of expressions can have 214 = 16384
possible values. However, since other than BH3-only mediated activation of Bax/Bak is
irrelevant to our work (the subject of our study is the Bcl-2 family mediated regulation of
MOMP), we exclude here the expression vectors where eBax = 1 or eBak = 1, reducing
thus the number of possible values to 212 = 4096. The value of the vector E remains
constant during each simulation.
Terminal states
The simulation is terminated at the time t once the state of the model S (S =
{s1, s2, . . . s14}) satisfies the following condition:
S(t) = S(t − n), n = 1, 2, . . . (3)
The condition described in the eq. (3), can imply either that the model converged to the
steady-state (n = 1), the model is oscillating between two different states (n = 2), or the
model is periodically orbiting through the set of states (n > 2).
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The state S(t), satisfying the condition (3) is the model’s terminal state S(tend). If the
S(tend) involves the states of both effectors, sBax(tend) = 0 and sBak(tend) = 0, then
the S(tend) is denoted as the “survival” state. If the S(tend) involves the states of one of the
effectors, either sBax(tend) = 1, or sBak(tend) = 1, then the S(tend) is simply denoted as the
“pro-MOMP” state.
Results
We have identified 1046 of the “survival” states, in which the model preserve the effectors
Bak and Bax inactive
The very first step was to find the terminal states in which the model is allowed to persist
without the activation of effectors (Bak and Bax) - survival states.
Therefore, for each of the 4096 expression vectors we performed 4096 simulations, each
simulation starting from one of the 4096 of the initial states (4096 = 212, that is the
number of possible initial states, including both sBax(t0) = 0 and sBak(t0) = 0).
We have identified 1046 unique survival states. The 388 of these states are logical
steady-states, remaining 678 of the survival states are oscillating. Hereafter, we assume
that these 1046 states represent basal, cellular conditions. To lead the cell out from such
survival state it requires the change of an expression vector which would initiate the state
transition. In the next step, we have investigated the transitions from the survival states
to other terminal states. To analyze these transitions, for each of the 1046 survival states,
we performed 4096 simulations. In each simulation we used one of the 4096 expression
vectors and one of the survival states to define the initial conditions. Thus we “exposed”
individual survival states to all the expression vectors and simulated the effect of changes
of cellular conditions on actual state of the Bcl-2 proteins family.
Around 70% of the 4.2 million (1046 × 4096) simulations led to survival, the remaining
30% of the simulations led to pro-MOMP terminal states, i.e. the states where at least one
of the effectors was found active.
We found 200 of the trapping states
During the analysis of the transitions between the survival states and the pro-MOMP
states, we have revealed an interesting finding. We have discovered the existence of 200
survival states from which the model cannot achieve the pro-MOMP states, regardless of
the vector of expressions. Moreover, the model, once found in such a “trapping” state, can
only be transitioned to another trapping state. The trapping of the Bcl-2 regulatory mech-
anism in one of these states would cause fatal malfunctioning of the MOMP regulation.
The cell arrested in one of such states becomes resistant to external apoptotic stimuli - a
condition which is one of the hallmarks of cancer cells [46]. Therefore, we denoted these
states as the “tumor” states.
In general, these states (the black squares in the Figure 2) exhibit strong imbalance in
activity of antiapoptotic vs BH3-only proteins. BH3-only proteins are overwhelmed by
activity of their antiapoptotic relatives. The activity of these compensates the positive
influence of the expression vectors on BH3-only proteins. According to the rule described
in eq. 1, in such a case the inactive BH3-only proteins remain inactive regardless of the
configuration of expression vectors. Therefore, changing the expression vector results
only in relocation of the model from one tumor state to another state, which will be
similarly imbalanced.
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Figure 2 Model’s survival states. The figure depicts the survival states – Bax, Bak representing nodes are
inactive. The squares are depicting the terminal states of the model within the “configuration space”, where
the configurations of states of nodes representing the antiapoptotic and BH3-only proteins are arranged
along y- and x-axis, respectively. The black squares represent the “tumor” states, while the green squares
represent the functionally “semioptimal” (light green) and “optimal” (dark green) survival states. While the first
mentioned allow only the activation of Bak (transition T4 in Figure 3), but not Bax, “optimal” states allow
activation of both effectors.
As we found, the cell can be “liberated” from a trapping state by pharmacological
inhibition of activity of antiapoptotic proteins (e.g. by competitive inhibition to prevent
neutralization of proapoptotic proteins). Especially effective would be the inhibition of
the Mcl-1, since the tumor states are overly abundant among the survival states involving
the activity of Mcl-1.
The existence of trapping tumor states indicates that relationships in Bcl-2 family allow
the establishment of the molecular populations of the Bcl-2 proteins which could be very
insensitive to apoptotic signaling. The apparent relationship between the activity of the
Mcl-1 and tumor states suggests that inhibition of Mcl-1 can be of special therapeutic
relevance of targeting tumor cells.
There are two functionally distinct subsets of survival states. Those which allowmodel to
activate the Bak, but not Bax and the states allowing activation of both effectors
The remaining 846 survival states can further be classified in two groups. The first group
consists of 54 survival states, from which the model can relocate to pro-MOMP states
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where the only active effector is Bak. From the 792 survival states of the second group,
the model can be turned to states with a single effector (Bak) activity, as well as to the pro-
MOMP states, where both effectors are active. The first group we denote as “semioptimal”
(the light green squares in Figure 2), the second one we denote as “optimal” (the dark
green squares in Figure 2).
Similarly, we distinguish several functionally distinct subsets among the pro-MOMP
states. Firstly, every pro-MOMP state may be classified according to the activity of effec-
tors. We have found 108 of the pro-MOMP states in which Bak is active, but Bax remains
inactive (the blue squares in Figure 3). Besides these, we also have found 132 of the pro-
MOMP states, in which both effectors are active (the red squares in Figure 3). However,
we haven’t found any such terminal state, where the Bax was active, while the Bak not,
indicating that such state is unaccessible by the model, regardless of expressions or initial
conditions.
Secondly, the first of the mentioned groups – Bak-active only, can further be divided in
two functionally distinct subgroups: states which allow additional activation of Bax (the
light blue squares in Figure 3), and those which don’t (the dark blue squares in Figure 3).
Figure 3 Model’s non-survival states. The figure depicts the non-survival states – either the Bax, or Bak is
active (blue squares), or both of them are active (red squares). The dark blue squares represent those states,
which allow subsequent activation of Bax, initiated by the change in the expressions. In contrast, the states
represented by the light blue squares suffer from the inability to allow the activation of Bax.
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It is very interesting that, while the first subgroup is accessible only from the “optimal”
survival states, the second one, can be accessed from both, “optimal” and “semioptimal”
survival states.
Survival to MOMP transition is irreversible
We have performed another series of simulations in which each of the pro-MOMP states
was used as the initial state of the model and each of the 4096 expression vectors were
iteratively applied to the model. We have found that it is impossible to turn the model
from any of the pro-MOMP states back to the survival one, regardless of the expression
vectors.
Irreversibility of the transition to pro-MOMP states originates in activity of effectors
itself. Mutual inhibitory relationships between effectors and corresponding antiapoptotic
proteins compensate the influence of the expression vectors on a given antiapoptotic pro-
tein. According to the rule described in eq. 1, in such a case inactive antiapoptotic protein
remains inactive and inhibition of effectors remains insufficient to suppress their activity,
regardless of the expression vector.
The transitions from the survival to MOMP are caused by expression changes of four
distinct types
When taking previous results together, we may distinguish six distinct groups of model’s
terminal states. Three of these groups associate survival states, characterized by no effec-
tors activity. Two groups associate pro-MOMP states, involving the activity of Bak, but
not Bax. The sixth group associates the states involving the activity of both effectors.
Assuming that the single effector activation is sufficient for the MOMP occurrence, four
types of survival-to-MOMP transitions can be distinguished (T1 – T4, see Figure 4).
We have analyzed the influence of the expression of the given protein on the initiation
of these transitions by means of multiple correlation coefficient -R2 (for more details see
Appendix).
Figure 5 shows that regardless of the transition type, the necessary condition for the
transition to MOMP is the expression of at least one of the activators (Bim, tBid). On
the other hand it seems that the expression of the Mcl-1 is the most significant factor
Figure 4 Transitions between the individual subsets of model’s terminal states. Using the same color
notation as in the Figures 2 and 3, the types of the model’s transitions between five functionally distinct
subgroups of model’s states are depicted.
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Figure 5 Multiple determination coefficients. R2 of the protein expressions calculated across the sets of
unique expressions vectors causing the survival-to-MOMP transitions of given type (for more details see
Appendix).
that prevents the MOMP. The statistical importance of the expression of activators and
the absence of Mcl-1 is common for both T1 and T2 transitions. Nevertheless, the tran-
sitions of type T2 - the activation of both effectors, additionally requires the absence of
Bcl-B expression. This finding is not unexpected as the Bcl-B is the only inhibitor of Bax
that is not suppressed by any of the BH3-only proteins [44]. Furthermore, the model pre-
dicts that after the T1 transition, the subsequent downregulation of Bcl-B can cause the
additional activation of Bax (the arrow pointing from the dark blue square to the red one,
Figure 4).
Transitions of the type T3 are similar to the T1 and T2. The only difference is that tran-
sitions of the type T3 occurs only in presence of the Bcl-2 expression. In other words,
expression of the antiapoptotic protein Bcl-2 prevents the transitions of type T3 and T4 –
transitions from optimal survival states to “dark blue” and “red” pro-MOMP states. If
model is located in one of the “light blue” states, subsequent down-regulation of Bcl-2
would allow its relocation to “dark blue” states (not depicted in Figure 4), but not to “red”
states.
The transitions of type T4 are caused by lack of the Mcl-1 expression while involving
the tBid expression. Since the number of semioptimal states is very small, the probability
of T4 transitions is low.
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We have found (data not shown) that the trapping of the model within the “trap-
ping” state occurs as the antiapoptotic expression disproportionately dominates over the
expression of BH3-only proteins. This points to the necessity of the balance between the
presence and synthesis of the both pro- and antiapoptotic Bcl-2 proteins within the cell.
Discussion
We have analyzed the Bcl-2 family interaction network using the Boolean network-
based computational model. Bcl-2 family members have been represented by nodes,
with binary encoded activity. The active (ON state) of the given node represents the
biologically active form of the represented protein. Nodes are mutually interacting
according to the given transition rules and the pre-defined relationship matrix, represent-
ing the currently known interactions among the Bcl-2 proteins. In addition, the model
operates under the influence of the vector of expressions that represent the biological
conditions. Change of vector of expressions is the primary driving force of the Bcl-2
regulatory mechanism. The expression vector allows introduction of synthesis and the
post-translational/-transcriptional activation of zymogens, if relevant for given protein.
Computational simulations of the model show that the majority of the expression vec-
tors lead the Bcl-2 family into set of states avoiding Bax and/or Bak activation. Our results
suggest, that once the antiapoptotic proteins significantly outnumber the BH3-only pro-
teins’ activity, the Bcl-2 family regulation may be seriously disrupted. Our model predicts,
that once this happens, even the subsequent activation of proapoptotic BH3-only pro-
teins cannot recover the proper MOMP. We have noted that the defects of MOMP
regulation are often associated with presence of Mcl-1 activity. However, the existence
of such “tumor facilitating” trap shows the importance of the balance between pro- and
antiapoptotic proteins maintained by their continuous expression.
Depending on the current state of the Bcl-2 family, certain configurations of the
incoming signals cause the activation of effectors Bak, and/or Bax. Statistically, the
most important signals are the truncation of Bid to tBid, the activation of Bim and the
downregulation of Mcl-1.
The ability of tBid to initiate apoptosis through MOMP has been well documented by
numerous works [45,47]. Similarly, extensive experimental support exists, proving that
activation of Bim [48-50] and downregulation of Mcl-1 [51,52] lead to apoptosis in cells.
It seems that the BH3-only mediated activation of Bak requires less specific conditions,
compared to the activation of Bax. This finding is well supported by several experimental
works, suggesting that MOMP initiated by BH3-only proteins occurs mainly through the
activation of Bak, not Bax [53-56]. According to the model, the activation of Bax is asso-
ciated with the downregulation of Bcl-w. Finally, our results confirm the irreversibility of
the effectors activation, which has been previously experimentally shown [57-59].
In spite of the simplicity of the Boolean-based approach the model provides remarkable
predictive and explanatory power. Moreover, the proposed model can be reutilized for
further analyses of robustness and stability of Bcl-2 family regulation of apoptosis.
Appendix: A calculation of multiple determination coefficients
This analysis is utilized to compare the importance of the expression of particular pro-
teins, with respect to the transition from certain group of states to another group of
states.
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Let’s have set of n unique expression vectors – E = {e1, e2, . . . e12} that cause the studied
transition. For each couple of nodes i, j we can calculate the phi coefficient:
φij = n11n00 − n10n01√n1•n0•n•0n•1 , (4)
where n00, n01, n10, n11, are counts of the following combinations of values ei, ej across
the set of expression vectors:
ei = 1 ei = 0 total
ej = 1 n11 n10 n1•
ej = 0 n01 n00 n0•
total n•1 n•0 n
The phi coefficient is a measure of association for two binary variables, similar to Pearson
correlation coefficient [60].
Thematrix of phi coefficients - Rφ , is then used as to calculate the coefficient of multiple
determination – R2:
R2i = cTi R−1φ,i ci, (5)
where the ci is the vector of values φij, j = 1, 2 . . . 12, i = j. ci is actually the vector
of correlations between the independent variables and the target variable – ei. cTi is the
transpose of c. The Rφ,i is the matrix Rφ , reduced by removing the i-th line and i-th col-
umn. Rφ,i is actually the matrix of correlations between the independent variables and
R−1φ,i is the inverse of the matrix Rφ,i.
Finally, the R2i was multiplied by −1 if the count of ei = 0 appearances was greater than
the count of ei = 1, across the set of expressions – the expression of the i-th node was
mostly absent among the expression vectors causing the given transition.
In case the values of i − th protein expression had no variability – either ei = 0, or
ei = 1 among all the expression vectors, the R2i was arbitrary set either to−1, or 1, respec-
tively. The correlations of any of the other expression with the ei were then excluded from
any other calculations. Such situation occurs in case of expression of Bcl-2 among the
transitions of the type T3 (see Figure 4).
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